Jounce Therapeutics Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Jounce Therapeutics (JNCE) PT Lowered to $15 at Baird
August 9, 2018 11:11 AM EDTBaird lowered its price target on Jounce Therapeutics (NASDAQ: JNCE) to $15.00 (from $20.00) while maintaining an Outperform rating following results.
Analyst Michael Ulz said the most notable update was the addition of two combination cohorts (ipiliumamb and pembrolizumab) to the ICONIC study, while the... More
Jounce Therapeutics (JNCE) Reports Q2 Loss of $0.14/Share
August 9, 2018 6:36 AM EDTJounce Therapeutics (NASDAQ: JNCE) reported Q2 EPS of ($0.14), versus ($0.11) reported last year. Revenue for the quarter came in at $19.38 million versus the consensus estimate of $12.91 million.
For earnings history and earnings-related data on Jounce Therapeutics (JNCE) click here.
... More